Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biocompatibility studies on peritoneal cells

N Topley1, G A Coles, J D Williams

  • 1Institute of Nephrology, University of Wales College of Medicine, Cardiff Royal Infirmary, United Kingdom.

Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Confirmation of a gene locus for medullary cystic kidney disease (MCKD2) on chromosome 16p12.

Kidney international·2001
Same author

Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels.

Kidney international·2001
Same author

Clinical research in peritoneal dialysis.

Contributions to nephrology·2000
Same author

Long-term peritoneal membrane changes.

Advances in renal replacement therapy·2000
Same author

In vivo exposure to bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improves ex vivo peritoneal macrophage function.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2000
Same author

Biocompatibility and new fluids.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·1999
Same journal

Translational insights into extracellular vesicles in peritoneal dialysis.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·2026
Same journal

Quercetin attenuates peritoneal fibrosis by upregulating ferroptosis-related glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (SLC7A11) in MeT-5A and rat models: Supported by clinical mRNA expression data.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·2026
Same journal

An in vitro comparison of bacterial touch contamination prevention between a novel APD cycler connector and existing APD connectors.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·2026
Same journal

What is the effect of the assistance on the risk of transfer to HD after an unplanned peritoneal dialysis initiation? A cohort study with data from the RDPLF.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·2026
Same journal

2026 ISPD Position Statement on tracking and reporting loss from PD therapy.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·2026
Same journal

Important factors in the choice of dialysis modality among Japanese patients initiating peritoneal dialysis.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·2026
See all related articles

Assessing peritoneal dialysis (PD) fluid biocompatibility requires better methods. Current in vitro studies are insufficient, necessitating improved in vivo and ex vivo models to guide fluid formulation for better patient outcomes.

Area of Science:

  • Biomaterials Science
  • Nephrology
  • Toxicology

Background:

  • Conventional in vitro studies for assessing peritoneal dialysis (PD) fluid biocompatibility have significant limitations.
  • There is a lack of in vivo data regarding host defense mechanisms and the clinical impact of alternative PD fluid formulations.
  • Defining optimal parameters for biocompatibility assessment is crucial for improving PD fluid safety and efficacy.

Purpose of the Study:

  • To review the challenges in evaluating PD fluid biocompatibility.
  • To highlight the inadequacies of current in vitro assessment methods.
  • To propose directions for developing improved PD fluid formulations and assessment strategies.

Main Methods:

  • Comprehensive review of existing literature on in vitro and in vivo studies of PD fluid biocompatibility.

Related Experiment Videos

  • Analysis of data concerning host defense and clinical outcomes related to PD fluid composition.
  • Evaluation of cell culture and ex vivo study designs for modeling in vivo conditions.

    • Main Results:

    • Current in vitro methods for assessing PD fluid biocompatibility are inadequate.
    • Insufficient in vivo data exists on host defense and the clinical effects of PD fluid changes.
    • There is a need to establish better parameters for biocompatibility assessment.

    Conclusions:

    • Future PD fluid formulations should minimize interference with host defense and maintain peritoneal membrane integrity for optimal ultrafiltration and clearance.
    • Cell culture and ex vivo studies must be designed to accurately reflect in vivo conditions.
    • Translating in vitro findings to clinical significance and demonstrating improved patient outcomes following fluid changes is essential.